Adele L. Boskey

Adele L. Boskey

Auto-generated profile, based on publicly available information

Adele L. Boskey

Musculoskeletal Integrity Program, Hospital for Special Surgery, New York, NY, USA

Research Focus & Metrics

Academic Career Length

53Years (1974-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2010 in Journal of Dental Research
Verified
Journal Article
Closed access
PDF file
ABA.L. Boskey
A.L. Boskey
RCR. Coleman
R. Coleman
Bones provide mechanical and protective function, while also serving as housing for marrow and a site for regulation of calcium ion homeostasis. The properties of bones do not remain constant with age; rather, they change throughout life, in some cases improving in function, but in others, function deteriorates. Here we review the modifications in the mechanical function and shape of bones, the bone cells, the matrix they produce, and the mineral that is deposited on this matrix, while presenting recent theories about the factors leading to these changes.

1 May 2007 in Biomaterials
Verified
Journal Article
Closed access
ABA Boskey
A Boskey
NPN Pleshkocamacho
N Pleshkocamacho

1 September 1998 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TXTianshun Xu
Tianshun Xu
PBPaolo Bianco
Paolo Bianco
LFLarry W. Fisher
Larry W. Fisher
GLGlenn Longenecker
Glenn Longenecker
ESErica Smith
Erica Smith
MYMarian F. Young
Marian F. Young

1 December 2001 in Tissue Engineering
Verified
Journal Article
Closed access
YHYuan-Di C. Halvorsen
Yuan-Di C. Halvorsen
DFDawn Franklin
Dawn Franklin
ABArden L. Bond
Arden L. Bond
DHDaron C. Hitt
Daron C. Hitt
CACatherine Auchter
Catherine Auchter
JGJeffrey M. Gimble
Jeffrey M. Gimble
Human adipose tissue represents an abundant reservoir of stromal cells with potential utility for tissue engineering. The current study demonstrates the ability of human adipose tissue-derived stromal cells to display some of the hallmarks of osteoblast differentiation in vitro. Following treatment with ascorbate, β-glycerophosphate, dexamethasone, and 1,25 dihydroxy vitamin D3, adipose tissue-derived stromal cells mineralize their extracellular matrix based on detection of calcium phosphate deposits using Alizarin Red and von Kossa histochemical stains. Fourier transform infrared analysis demonstrates the apatitic nature of these crystals. Mineralization is accompanied by increased expression or activity of the osteoblast-associated proteins osteocalcin and alkaline phosphatase. These and other osteoblast-associated gene markers are detected based on polymerase chain reaction. In contrast, the adipocyte gene markers—leptin, lipoprotein lipase, and peroxisome proliferator activated receptor γ2—are reduced under mineralization conditions, consistent with the reciprocal relationship postulated to exist between adipocytes and osteoblasts. The current work supports the presence of a multipotent stromal cell population within human extramedullary adipose tissue. These findings have potential implications for human bone tissue bioengineering.

1 September 1998 in Bone
Verified
Journal Article
Open access
ABA.L Boskey
A.L Boskey
SGS Gadaleta
S Gadaleta
CGC Gundberg
C Gundberg
SDS.B Doty
S.B Doty
PDP Ducy
P Ducy
GKG Karsenty
G Karsenty
Osteocalcin, the gamma-carboxyglutamic acid-containing protein, which in most species is the predominant noncollagenous protein of bone and dentin, has been postulated to play roles in bone formation and remodeling. Recently, genetic studies showed that osteocalcin acts as an inhibitor of osteoblast function. Based on von Kossa staining and measurement of mineral apposition rates in tetracycline-labeled bones, osteocalcin knockout animals were reported to have no detectable alterations in bone mineralization. To test the hypothesis that, in addition to regulating osteoblastic activity, osteocalcin is involved in regulating mineral properties, a more sensitive assay of mineralization, Fourier transform infrared microspectroscopy (FT-IRM) was used to study thin sections of femora of 4-week-, 6-month- (intact and ovariectomized), and 9-month-old wild-type and osteocalcin-knockout mice. FT-IRM spectra provided spatially resolved measures of relative mineral and carbonate contents, and parameters indicative of apatite crystal size and perfection. No differences were detected in the mineral properties of the 4-week-old knockout and wild-type mice indicating that the mineralization process was not altered at this time point. Six-month-old wild-type animals had higher mineral contents (mineral:matrix ratios) in cortical as compared with trabecular bones; mineral contents in knockout and wild-type bones were not different. At each age studied, carbonate:phosphate ratios tended to be greater in the wild-type as compared with knockout animals. Detailed analysis of the phosphate nu1,nu3 vibrations in the spectra from 6-month-old wild-type animals indicated that the crystals were larger/more perfect in the cortical as opposed to the trabecular bones. In contrast, in the knockout animals' bones at 6 months, there were no differences between trabecular and cortical bone in terms of carbonate content or crystallite size and perfection. Spectral parameters of the cortical and trabecular bone of the knockout animals resembled those in the wild-type trabecular bone and differed from wild-type cortical bone. In ovariectomized 6-month-old animals, the mineral content (mineral:matrix ratio) in the wild-type cortices increased from periosteum to endosteum, whereas, in the knockout animals' bones, the mineral:matrix ratio was constant. Ovariectomized knockout cortices had lower carbonate:phosphate ratios than wild-type, and crystallite size and perfection resembled that in wild-type trabeculae, and did not increase from periosteum to endosteum. These spatially resolved data provide evidence that osteocalcin is required to stimulate bone mineral maturation.

4 December 2013 in BoneKEy Reports
Verified
Journal Article
Closed access
ABAdele L Boskey
Adele L Boskey
The composition of a bone can be described in terms of the mineral phase, hydroxyapatite, the organic phase, which consists of collagen type I, noncollagenous proteins, other components and water. The relative proportions of these various components vary with age, site, gender, disease and treatment. Any drug therapy could change the composition of a bone. This review, however, will only address those pharmaceuticals used to treat or prevent diseases of bone: fragility fractures in particular, and the way they can alter the composition. As bone is a heterogeneous tissue, its composition must be discussed in terms of the chemical makeup, properties of its chemical constituents and their distributions in the ever-changing bone matrix. Emphasis, in this review, is placed on changes in composition as a function of age and various diseases of bone, particularly osteoporosis. It is suggested that while some of the antiosteoporotic drugs can and do modify composition, their positive effects on bone strength may be balanced by negative ones.